



ASX ANNOUNCEMENT

ASX:NSB

Despatch of Non-Renounceable Entitlement Offer

Perth, Australia; November 20, 2018: NeuroScientific Biopharmaceuticals Limited (**ASX:NSB**) advises that it has today despatched a copy of the non-renounceable entitlement offer prospectus and an entitlement and acceptance form to eligible shareholders. The prospectus contains information of the offer announced on 9 November 2018.

The offer is currently scheduled to close at 5:00pm (WST) on Thursday, 29 November 2018.

Eligible shareholders who have questions relating to acceptance of the offer should contact NSB's share registry, Automic Group, on 1300 288 664 (within Australia) or +61 2 9698 5414 (international) between 8:30am and 5:00pm (AEST) on business days during the offer period.

Any other questions concerning the offer should be directed to Thomas Spencer, Company Secretary on + 61 8 6382 1804.

About Neuroscientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

Contacts

Mr Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Thomas Spencer
CFO & Company Secretary
ir@neuroscientific.com
+61 491 108 250